Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2022-12-13 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It reports on a merger agreement and related announcements, including a press release and social media posts about presentations at a medical meeting. The document includes forward-looking statements and references to a definitive proxy statement filed separately. It does not contain financial statements or detailed financial analysis but rather serves as a regulatory disclosure of a corporate event and related communications. The document is not an annual or quarterly report, earnings release, proxy solicitation, or management discussion. It is a regulatory filing reporting a material event and related disclosures, fitting the category of Regulatory Filings (RNS).
2022-12-13 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It includes disclosures about a merger agreement and related press releases and social media posts. The filing references a merger transaction and includes forward-looking statements, solicitation information, and exhibits such as a press release and social media posts. The document is not a full financial report, earnings release, or proxy statement but rather a current report disclosing material events and communications related to the merger. The presence of Rule 425 communications and the nature of the content indicate this is a Regulatory Filing (RNS) rather than a detailed financial report or proxy solicitation. The document length and content confirm it is not a brief announcement or a full annual/interim report but a current report on material events.
2022-12-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It reports a compensatory arrangement for the interim CEO and Chairman, including a bonus award and benefits continuation contingent on a merger transaction. The document references the merger agreement and proxy materials filed on Form S-4, but it itself is a standalone current report about management compensation and merger-related arrangements. It does not contain full financial statements or detailed financial analysis, nor is it a proxy solicitation or definitive proxy statement itself. The key item reported is the departure/election/compensatory arrangement of a director/officer, which fits the Board/Management Information category. The document is not a report publication announcement, certification, or general regulatory filing. Therefore, the best classification is Board/Management Information (MANG). Confidence is high given the clear Item 5.02 heading and content focused on management compensation and merger-related arrangements.
2022-12-08 English
425 Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It reports a compensatory arrangement for the interim CEO and Chairman, including a bonus and health insurance continuation, contingent on a merger transaction. The document references the merger agreement and the filing of a definitive proxy statement/prospectus on Form S-4 related to the merger. It also includes forward-looking statements and solicitation disclaimers. The content focuses on management changes and arrangements rather than financial results or detailed financial statements. The key item reported is the departure/election/appointment and compensatory arrangements of certain officers, which aligns with Board/Management Information filings. The document is not an earnings release, annual report, proxy solicitation, or merger filing itself but a current report announcing management compensation related to a merger. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (9844 characters) supports it being a substantive filing rather than a brief announcement or certification.
2022-12-08 English
Regulatory Filings 2022
Regulatory Filings
2022-12-05 English
424B3
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed filing pursuant to Rule 424(b)(3) related to a proposed merger between Gemini Therapeutics, Inc. and Disc Medicine, Inc. It includes extensive information about the merger agreement, exchange ratios, stockholder meetings, voting proposals, and related financing. The text references a proxy statement/prospectus multiple times and includes detailed merger terms and stockholder approval requests. This type of document is characteristic of merger communications and proxy solicitation materials. It is not a simple announcement or a brief summary but a comprehensive filing related to merger proposals and shareholder voting. Therefore, the most appropriate classification is 'Proxy Solicitation & Information Statement' (PSI).
2022-12-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.